Navigation Links
Comparing Psoriasis Treatments

A new study shows two common treatments for psoriasis -- methotrexate and cyclosporine -- are equally effective in relieving symptoms of the disease. //

Researchers in Amsterdam studied nearly 90 patients with moderate-to-severe psoriasis. Half of the patients were given methotrexate, and the other half were treated with cyclosporine. Researchers evaluated the side effects and effectiveness of each drug. They also recorded the time patients were in remission and assessed their quality of life. None of the participants had previously been treated with methotrexate or cyclosporine.

Results of the study show the overall response rate for both drugs was more than 90 percent. Seventeen patients in the methotrexate group and 14 patients in the cyclosporine group reached nearly complete remission. Twenty-six patients in the methotrexate group and 30 patients in the cyclosporine group achieved partial remission. However, after 16 weeks of treatment, no significant difference in overall effectiveness was seen between the two groups.

More than 100 patients in the methotrexate group and more than 150 patients in the cyclosporine group reported side effects. More patients in the methotrexate group reported nausea, and patients in the cyclosporine group were more likely to report headaches. There were no significant reported differences in quality of life between the two groups.

Authors of the study say the overall effectiveness of methotrexate is similar to that of cyclosporine. They conclude, "Differences between the treatments in terms of side effects, long-term adverse effects, ease of administration, and costs can be used to guide treatment decisions in individual cases."
'"/>




Page: 1

Related medicine news :

1. Comparing Breast surgery techniques
2. Comparing heart disease treatments
3. New and unique treatment for Psoriasis patients
4. Psoriasis Increases Cancer Risk
5. Help for Psoriasis
6. Managing Patients With Psoriasis
7. Effective Treatment Option For Psoriasis
8. Smoking Aggravates Psoriasis
9. Remicade Emerges as a Treatment for Patients Suffering From Psoriasis Disorder
10. Short-Term Topical Corticosteroid May Offer Relief for Certain Type of Psoriasis
11. Psoriasis raises risk for heart attack
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Comparing Psoriasis Treatments

(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among its founding ... since its inception more than 35 years ago. A pilot program begun by the ... - and, not just those intent on pursuing careers in these fields. The program ...
(Date:9/1/2015)... ... September 01, 2015 , ... Royal River Natural Foods, a locally-owned independent natural ... women for 19 years and found that, among those who had a stroke, people ... report is part of the September 2015 issue of “Natural Insights for Well Being,” ...
(Date:9/1/2015)... Boston, MA (PRWEB) , ... September 01, 2015 , ... ... the little-known and incurable disease, facioscapulohumeral muscular dystrophy (FSHD), will be the beneficiary of ... has the same mission – to raise awareness of the FSH Society and further ...
(Date:9/1/2015)... , ... September 01, 2015 , ... SC&H Group, a ... which includes being named a “Best of the Best” firm in the U.S., as ... named the “Best of the Best” in the U.S., selected exclusively on performance in ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... the 2015-2016 Distinguished Nurse Scholar-in Residence at the Institute of Medicine (IOM) of ... of Biomedical Informatics at Columbia University School of Nursing. A member of the ...
Breaking Medicine News(10 mins):Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:Columbia Nursing’s Suzanne Bakken Named Distinguished Institute of Medicine Nurse Scholar-in-Residence 2
... diagnosed with primary open angle glaucoma (POAG) are not ... to a study. ,The study is the ... utilize longitudinal data from a nationally representative sample of ... use and surgeries among adults aged 65 and older ...
... says a new study although scientists warn too much reduction ... 1930s it was found that laboratory animals fed a calorie-restricted ... diabetes and cardiovascular disease, but until now, there has been ... lives. ,Now researchers, led by Andrew Dillin at ...
... ready to fight against cancer for the fifth time . ... cancer for the fifth time, started a six-week bout of chemotherapy ... ,He has battled cancer on and off for the last ... course, it's not the greatest news I've ever had but I ...
... babies prone to SIDS and serious health ailments. ... Children in Glasgow have closed in on the possible risk ... risks of cot death. ,Professors Ann Burchell and ... are team leaders of a research group that has zeroed ...
... for promoting good health. The latest news about ... ,Researchers from the University of Wisconsin have ... the infection and avoid what could otherwise lead to ... at the University of Wisconsin introduced this unique therapy ...
... with severe depression who don't respond to other treatments, ... stages of the illness, according to an article ... has been shown to be a highly effective, safe, ... bipolar disorder, and schizophrenia," writes Dr. Stephen Taylor of ...
Cached Medicine News:Health News:Bobby Robson Diagnosed With Cancer for Fifth Time 2Health News:Despite Being Effective Electroconvulsive Therapy is Underused for Severe Depression 2
(Date:9/1/2015)... , Sept. 1, 2015  Results from an interim ... demonstrate that 5g of idarucizumab enabled emergency surgery ... patients treated with dabigatran (Pradaxa ® dabigatran ... anticoagulant effect of dabigatran enabled patients to be ... time of 1.7 hours between administration of idarucizumab ...
(Date:9/1/2015)... 1, 2015   Ivenix Inc. , a ... system, closed on a $42M round of equity ... Cardinal Partners, CICA, Inc., Easterly Capital, Fidelity Biosciences, ... round. This financing will support the company,s efforts ... Partners LLC acted as the exclusive placement agent ...
(Date:9/1/2015)... 2015 Within just two years after reaching ... rapidly reached 3,000 employees worldwide. This increase is ... injectable drug delivery market and SHL,s effective commitment, ... in the design and manufacturing of auto injectors ... manufacturing capabilities, a lean supply chain, strong partnerships, ...
Breaking Medicine Technology:New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3SHL Group Reaches Major Milestone of 3000 Employees 2
... 8, 2011 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ... year 2010 financial results before the NASDAQ Global Select Market ... Lief, Arena,s President and Chief Executive Officer, will host a ... Time) to discuss the financial results for the fourth quarter ...
... Sciences: OTC Bulletin Board: RBCL ) -- RBC ... care and pain management products, today reported a 13% increase ... ended December 31, 2010, compared to net sales of $24.9 ... Company reported net earnings of $558,000, or $0.02 per diluted ...
Cached Medicine Technology:Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 11 3RBC Life Sciences Reports Sales and Earnings Growth in 2010 2RBC Life Sciences Reports Sales and Earnings Growth in 2010 3
Delicate Desmarres lid retractors, round serrated handle, very thin blades, polished finish, size 1....
Desmarres Lid Retractor thin solid blades. Size 2....
The Storz Protege is an anterior segment unit only....
... all the features of phaco systems costing ... minimal maintenance. Small, light and tough enough ... Lowest cost reusable tubing kit can be ... there a price objection to purchasing a ...
Medicine Products: